Logo-jnp
J Nephropathol. 2023;12(1): e17355.
doi: 10.34172/jnp.2022.17355
  Abstract View: 216
  PDF Download: 103

Review Article

Administration of finerenone in chronic kidney disease

Mohsen Akhavan Sepahi 1 ORCID logo, Elham Emami 2 ORCID logo, Akshaya Ann Joseph 3 ORCID logo, Shakiba Hassanzadeh 4 ORCID logo, Mohammad Reza Razavi 1* ORCID logo

1 Department of Pediatric Nephrology, School of Medicine, Qom University of Medical Sciences, Qom, Iran
2 Pediatric Nephrology Research Center (PNRC), Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Emam Hosein Hospital, Tehran, Iran
3 Department of Pharmaceutical Sciences, the University of British Columbia, Vancouver, BC, Canada
4 Division of Pathology, Nickan Research Institute, Isfahan, Iran
*Corresponding Author: Corresponding author: Mohammad Reza Razavi, Email: , Email: Dr.rezarazavimd@gmail.com

Abstract

Spironolactone is a first-generation and non-selective mineralocorticoid receptor antagonist (MRA). It is extensively well-studied and recommended due to increased accessibility for patients. Unfortunately, it is often discontinued in several cases due to its association with hyperkalemia. The apparent benefit of eplerenone over spironolactone is its mineralocorticoid receptor (MR) selectivity. However, it is also characterized by low-potency and higher cost compared to spironolactone. The high adverse-effect profile of spironolactone and eplerenone has led to the innovation of novel medications such as non-steroidal MRAs. Among these medications, finerenone is the most advanced agent. Finerenone is associated with decreased proteinuria, reduced risk of hyperkalemia and increased preservation of renal function with comparable benefit in heart failure compared to selective and nonselective MRAs. The nonsteroidal structure of finerenone affects mineralocorticoid receptor binding, lipophilicity and polarity which have potent effects on distribution, the degree of attachment to blood proteins, transportation, and tissue diffusion.

Implication for health policy/practice/research/medical education:

The available non-selective mineralocorticoid receptor antagonist (MRA) such as spironolactone and eplerenone have high adverse-effect profiles. Therefore, novel non-steroidal MRAs have been studied and discovered during recent years. Among these drugs, finerenone is associated with decreased proteinuria, reduced risk of hyperkalemia, and increased preservation of renal function with comparable benefits in heart failure to selective and nonselective MRAs.

Please cite this paper as: Akhavan Sepahi M, Emami E, Joseph AA, Hassanzadeh S, Razavi MR. Administration of finerenone in chronic kidney disease. J Nephropathol. 2023;12(1):e17355. DOI: 10.34172/jnp.2022.17355.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 217

Your browser does not support the canvas element.


PDF Download: 103

Your browser does not support the canvas element.

Submitted: 13 Oct 2021
Accepted: 03 Jan 2022
ePublished: 14 Feb 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)